5.495USD+0.09%Mkt Cap: 1.61B USDP/E: —Last update: 2026-05-26
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central ner…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap1.61B USD
Enterprise Value1.38B USD
Revenue (TTM)7.47M USD
Gross Profit7.47M USD
Net Income (TTM)-109.00M USD
Revenue/Share0.0220 USD
Last Price5.495 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees99
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-12.52
PEG—
EV/EBITDA-10.53
EV/Revenue185.24
P/S213.09
P/B6.40
EPS (TTM)-0.38
EPS (Forward)-0.44
52W Range
2.25064% of range7.300
52W High7.300 USD
52W Low2.250 USD
Profitability
Gross Margin100.00%
Oper. Margin-1774.37%
EBITDA Margin0.00%
Profit Margin-1115.27%
ROE-44.14%
ROA-31.75%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-93.09M USD
CapEx (TTM)738.00K USD
FCF Margin-983.11%
FCF Yield-4.57%
Net Debt-208.03M USD
Net Debt/EBITDA1.58
Balance Sheet
Debt/Equity0.28
Current Ratio14.04
Quick Ratio13.76
Book Value/Sh0.8660 USD
Cash/Share0.9620 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)12.23 USD
Target Range8.000 USD – 19.00 USD
# Analysts13
Ownership
Shares Out.287.36M
Float196.96M
Insiders10.62%
Institutions95.70%
Short Interest
Short Ratio14.1d
Short % Float14.19%
Short % Out.13.94%
Shares Short40.05M
Short (prev mo.)42.27M
Technical
SMA 505.462 (+0.6%)
SMA 2004.612 (+19.1%)
Beta1.23
S&P 52W Chg28.31%
Avg Vol (30d)2.79M
Avg Vol (10d)2.41M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—